Compile Data Set for Download or QSAR
maximum 50k data
Found 2959 with Last Name = 'harper' and Initial = 'b'
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384842(N-[(1R)-1-(4-cyclopropyl-3- fluorophenyl)-2,2-dime...)
Affinity DataKi:  0.0300nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357210(US10214512, Example 151-a)
Affinity DataKi:  0.0400nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384991(2-(dimethylamino)-N-{(1S)-2- hydroxy-2-methyl-1-[4...)
Affinity DataKi:  0.0730nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357161(US10214512, Example 117)
Affinity DataKi:  0.0800nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357017((S) 5-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)-2-(25-...)
Affinity DataKi:  0.0900nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357214(US10214512, Example 152-a)
Affinity DataKi:  0.0900nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384842(N-[(1R)-1-(4-cyclopropyl-3- fluorophenyl)-2,2-dime...)
Affinity DataKi:  0.100nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357026(5-(5-Chloro-2-(1H-tetrazol-1-yl)phenyl)-2-(24-((me...)
Affinity DataKi:  0.100nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357188(US10214512, Example 143-b)
Affinity DataKi:  0.100nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384950(N-{(1R)-2,2-dimethyl-1-[4- (trifluoromethyl)phenyl...)
Affinity DataKi:  0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384822(2-(dimethylamino)-N-{(1R)-2,2- dimethyl-1-[4-(pent...)
Affinity DataKi:  0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384860(N-{(1R)-1-[4-(1,1- difluoroethyl)phenyl]-2,2- dime...)
Affinity DataKi:  0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357058(US10214512, Example 38)
Affinity DataKi:  0.110nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384819(N-[(1R)-1-(4-cyclopropylphenyl)-2,2- dimethylpropy...)
Affinity DataKi:  0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384821(2-(dimethylamino)-N-{(1R)-1-[2- fluoro-4-(trifluor...)
Affinity DataKi:  0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357166(US10214512, Example 122 | US10214512, Example 125)
Affinity DataKi:  0.110nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384789(US10285989, Example 2)
Affinity DataKi:  0.110nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384887(2-(dimethylamino)-N-[(1R)-2,2- dimethyl-1-{4- [(tr...)
Affinity DataKi:  0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384887(2-(dimethylamino)-N-[(1R)-2,2- dimethyl-1-{4- [(tr...)
Affinity DataKi:  0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384988(2-(dimethylamino)-N-{(1S)-1-[3- fluoro-4- (trifluo...)
Affinity DataKi:  0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357173(US10214512, Example 129)
Affinity DataKi:  0.120nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384885(2-(dimethylamino)-N-{(1R)-1-[3-fluoro- 4-(trifluor...)
Affinity DataKi:  0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384819(N-[(1R)-1-(4-cyclopropylphenyl)-2,2- dimethylpropy...)
Affinity DataKi:  0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384860(N-{(1R)-1-[4-(1,1- difluoroethyl)phenyl]-2,2- dime...)
Affinity DataKi:  0.120nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384821(2-(dimethylamino)-N-{(1R)-1-[2- fluoro-4-(trifluor...)
Affinity DataKi:  0.130nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357206(US10214512, Example 150-a)
Affinity DataKi:  0.130nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357153((Z)-5-(3-Chloro-2,6-difluorophenyl)-2-(15-ethyl-24...)
Affinity DataKi:  0.130nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357057(US10214512, Example 37)
Affinity DataKi:  0.130nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357025(2-(25-carboxy-4-oxo-3-aza-1(1,3),2(1,2)-dibenzenac...)
Affinity DataKi:  0.130nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384949(N-{(1R)-2,2-dimethyl-1-[4- (trifluoromethyl)phenyl...)
Affinity DataKi:  0.140nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384822(2-(dimethylamino)-N-{(1R)-2,2- dimethyl-1-[4-(pent...)
Affinity DataKi:  0.140nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384885(2-(dimethylamino)-N-{(1R)-1-[3-fluoro- 4-(trifluor...)
Affinity DataKi:  0.140nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357170(US10214512, Example 126)
Affinity DataKi:  0.140nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357143((Z)-5-(5-Chloro-2-(difluoromethoxy)phenyl)-2-(24-(...)
Affinity DataKi:  0.140nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357192(US10214512, Example 145-a)
Affinity DataKi:  0.140nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357196(US10214512, Example 146-a)
Affinity DataKi:  0.140nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357231(US10214512, Example 166-a)
Affinity DataKi:  0.140nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357110(9-(5-(5-chloro-2-(1h-tetrazol-1-yl)phenyl)-1-oxido...)
Affinity DataKi:  0.140nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357172(US10214512, Example 128)
Affinity DataKi:  0.140nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384908((S)- or (R)-2-(dimethylamino)-N-{1-[2- fluoro-4-(p...)
Affinity DataKi:  0.150nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384928(N-[(1R)-2- methyl-1-{4- [(trifluoromethyl) sulfany...)
Affinity DataKi:  0.150nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357174(US10214512, Example 130)
Affinity DataKi:  0.150nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357171(US10214512, Example 127)
Affinity DataKi:  0.150nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384789(US10285989, Example 2)
Affinity DataKi:  0.150nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357099(5-(3-chloro-2,6-difluorophenyl)-2-((5R,9S)-15-fluo...)
Affinity DataKi:  0.160nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKallikrein-1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357210(US10214512, Example 151-a)
Affinity DataKi:  0.160nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384949(N-{(1R)-2,2-dimethyl-1-[4- (trifluoromethyl)phenyl...)
Affinity DataKi:  0.170nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384857(N-{(1R)-1-[4-(difluoromethyl)-2- fluorophenyl]-2,2...)
Affinity DataKi:  0.170nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphodiesterase(Macaca mulatta (Rhesus macaque))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM384884(2-(dimethylamino)-N-{(1R)-2,2- dimethyl-1-[4- (tri...)
Affinity DataKi:  0.170nMAssay Description:The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM357155((Z)-5-(3-chloro-2,6-difluorophenyl)-2-(24-((methox...)
Affinity DataKi:  0.170nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 2959 total ) | Next | Last >>
Jump to: